| Q37070395 | A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease |
| Q37057317 | Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease |
| Q42519276 | Alterations of acetylcholinesterase activity after traumatic brain injury in rats |
| Q50748097 | Altitude acclimatization improves submaximal cognitive performance in mice and involves an imbalance of the cholinergic system. |
| Q55395388 | Analogous β-Carboline Alkaloids Harmaline and Harmine Ameliorate Scopolamine-Induced Cognition Dysfunction by Attenuating Acetylcholinesterase Activity, Oxidative Stress, and Inflammation in Mice. |
| Q47686054 | Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment. |
| Q35064960 | Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? |
| Q35237100 | Biological markers for early detection and pharmacological treatment of Alzheimer's disease |
| Q38150708 | Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations |
| Q37769104 | Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives |
| Q33556189 | Biomarkers in translational research of Alzheimer's disease |
| Q43168358 | Central nervous system effects of haloperidol on THC in healthy male volunteers |
| Q40285261 | Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy |
| Q35882869 | Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment |
| Q50726972 | Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. |
| Q48428964 | Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia |
| Q26764933 | Cholinergic imaging in dementia spectrum disorders |
| Q28067006 | Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region |
| Q48794870 | Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. |
| Q37138478 | Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. |
| Q48364388 | Comparative behavioral and neurochemical analysis of phenytoin and valproate treatment on epilepsy induced learning and memory deficit: Search for add on therapy |
| Q34558884 | Dementia prevention, intervention, and care. |
| Q37610784 | Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease |
| Q51911470 | Differentiating Alzheimer's disease from subcortical vascular dementia with the FAB test. |
| Q33586027 | Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease |
| Q37109750 | Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report |
| Q34965949 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics |
| Q43229409 | Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model |
| Q36544994 | Donepezil: a review |
| Q36808057 | Donepezil: an update |
| Q45663984 | Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET. |
| Q31011918 | Dysfunctional Presynaptic M2 Receptors in the Presence of Chronically High Acetylcholine Levels: Data from the PRiMA Knockout Mouse |
| Q47878674 | Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease |
| Q34746698 | Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study |
| Q48500758 | Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial |
| Q46857413 | Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil |
| Q49022359 | Function of Plectranthus barbatus herbal tea as neuronal acetylcholinesterase inhibitor. |
| Q45942055 | High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. |
| Q37459699 | History of falls in Parkinson disease is associated with reduced cholinergic activity |
| Q57052929 | Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant M1 muscarinic acetylcholine receptor agonist |
| Q36743706 | Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders |
| Q52593214 | In vitro pharmacological characterization and in vivo validation of LSN3172176 a novel M1 selective muscarinic receptor agonist tracer molecule for positron emission tomography (PET). |
| Q93055019 | Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition? |
| Q31117740 | Neurobiological early diagnosis of Alzheimer's disease |
| Q37639158 | Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection |
| Q38132755 | Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors? |
| Q57282358 | Neurophysiological signals as predictive translational biomarkers for Alzheimer's disease treatment: effects of donepezil on neuronal network oscillations in TgF344-AD rats |
| Q60950139 | Non-Dopaminergic Therapies |
| Q38166972 | PET probes for imaging brain acetylcholinesterase |
| Q38606300 | Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play? |
| Q30244035 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration |
| Q36861445 | Physical activity and cognition in Alzheimer's disease: relationship to vascular risk factors, executive functions and gait |
| Q37150643 | Positron emission tomography imaging in dementia. |
| Q47624462 | Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. |
| Q50420909 | Recent advances in cholinergic imaging and cognitive decline-Revisiting the cholinergic hypothesis of dementia |
| Q44436180 | Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease |
| Q81908489 | Rivastigmine for dementia associated with Parkinson's disease |
| Q64072599 | Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial |
| Q41975639 | Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action |
| Q57729852 | Study of the effect of antidepressant drugs and donepezil on aluminum-induced memory impairment and biochemical alterations in rats |
| Q37511433 | Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease |
| Q31105327 | The application of positron-emitting molecular imaging tracers in Alzheimer's disease |
| Q49077948 | The dysexecutive syndromes |
| Q33624389 | The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging |
| Q37688880 | The use of PET in Alzheimer disease |
| Q55023604 | Theta Burst Stimulation Enhances Connectivity of the Dorsal Attention Network in Young Healthy Subjects: An Exploratory Study. |
| Q33836947 | Update on the Pharmacological Treatment of Alzheimers Disease |
| Q34078785 | Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples |
| Q35781558 | Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). |